Cabaletta Bio Gets FDA OK to Study CABA-201 in Generalized Myasthenia Gravis
November 06 2023 - 7:55AM
Dow Jones News
By Colin Kellaher
Cabaletta Bio has won Food and Drug Administration authorization
to launch a Phase 1/2 study of its CABA-201 investigational therapy
in patients with the rare autoimmune disease generalized myasthenia
gravis.
The Philadelphia clinical-stage biotechnology company on Monday
said the green light expands the clinical development of its lead
product candidate beyond rheumatology into neurology, adding that
it plans to initiate a study across two parallel patient cohorts
based on autoantibody status.
Cabaletta--which previously received FDA approvals to study
CABA-201 in lupus, myositis and systemic sclerosis--said it is on
track to deliver initial clinical data from patients with lupus
and/or myositis in the first half of 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 06, 2023 07:40 ET (12:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Oct 2023 to Oct 2024